We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-84.00 | -0.77% | 10,830.00 | 10,826.00 | 10,830.00 | 10,934.00 | 10,764.00 | 10,914.00 | 306,125 | 11:35:31 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 28.15 | 167.61B |
International stocks trading in New York closed higher on Monday.
AstraZeneca PLC (AZN ,AZN.LN) was among the companies with ADRs that traded actively.
The BNY Mellon index of American depositary receipts rose 1.3% to 130.48. The European index increased 1.2% to 129.88, the Asian index improved 1.3% to 139.94, the Latin American index rose 1.6% to 163.61 and the emerging markets index increased 1.8% to 222.52.
AstraZeneca's ADRs rose 4.8% to $32.78 on Monday following Friday's announcement that the drug maker's lung-cancer treatment Tagrisso won U.S. regulatory approval after an unusually quick development process that took just 2 1/2 years. Tagrisso, previously known as AZD9291, is the first drug for a subset of lung-cancer patients whose tumors have spread and developed a treatment-resistant mutation called T790M. Another treatment for this group of patients, rociletinib from Clovis Oncology Inc., is being reviewed by U.S. regulators. Clovis said Monday that the Food and Drug Administration asked for additional data on rociletinib, a request that could delay potential approval of the treatment.
Banco Bradesco SA (BBDO, BBD, BBDC4.BR) plans to increase its capital by 3 billion reais ($782 million) by issuing 164.8 million new shares. The new shares will be divided almost evenly between ordinary and preferred shares. The Brazilian lender's shareholders will vote on the plan Dec. 17, the bank said Monday in a regulatory filing. ADRs rose 3% to $6.29.
JD.com (JD) reported that its third-quarter revenue grew 52% to $6.9 billion though the Chinese e-commerce company said its quarterly net loss widened sharply from the year-earlier period, with much of the loss stemming from higher expenses related to JD.com's expansion of its direct sales business and increased spending on marketing. The company expects sales for the current quarter to increase between 47% and 51%. ADRs rose 7.7% to $28.81.
Royal Dutch Shell PLC (RDSA, RDSA.LN) said that it is replacing the president of its Canadian subsidiary less than a month after abandoning a major oil sands project in the country. The moves come at a turbulent time for the energy industry as a prolonged slump in prices has squeezed profits, especially for high-cost operations such as oil sands and shale oil. ADRs fell 2.6% to $49.59.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 16, 2015 17:37 ET (22:37 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions